-

Medable to Present at Jefferies Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading evidence-generation platform provider for modern clinical trials, today announced that Medable Co-founder and CEO Michelle Longmire will present at the Jefferies Global Healthcare Conference. The live presentation will take place on Thursday, June 6, 2024, at 3:30p.m. ET in New York City, New York.

The Management Team will also be available for 1:1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.

For more information, please contact:
Burak Over
SVP, Corporate Development & Investor Relations
burak@medable.com

To learn more about Medable, visit medable.com.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and ranked #398 on the Inc. 5000 in 2023.

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI

Release Versions

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Social Media Profiles
More News From Medable Inc.

New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment. The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value and experience d...

Medable Introduces Digital Data Flow Agent, Laying the Foundation for End-to-End Agentic Clinical Development

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic clinical development, today announced its Digital Data Flow (DDF) Agent, which automatically transforms static clinical trial protocols into structured, machine-readable data that can be continuously used across the clinical development lifecycle.Traditionally, clinical trial protocols are static documents that require extensive manual interpretation and re-creation across many downstream systems. Medab...

Medable Launches Agentic Accelerator Program to Help Life Sciences Companies Deploy Agentic AI Across Clinical Lifecycle

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI-powered clinical development, today announced its Agentic Accelerator Program to help life sciences companies transform clinical development with agentic AI. The program includes onboarding, integration support, governance, and change management to enable sponsors and contract research organizations to gain value from AI agents from day one. Surprisingly, only 22% of life sciences leaders have scale...
Back to Newsroom